Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis - Wikidata - wikimedia - TriplyDB

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis

http://www.wikidata.org/entity/Q35351243

about

Phosphate control in dialysis Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer.Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease.Use of nicotinamide to treat hyperphosphatemia in dialysis patients.Nicotinamide and phosphate homeostasis in chronic kidney disease.Niacin for phosphate control: A case of David versus Goliath.Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients.

P2860

Q27025339-E8F624EA-A5C0-4346-A159-D3C46F6BA794 Q30317153-2E1736E2-92CF-4103-80E3-13D6BCF07B5E Q33432308-D8EA68F0-3339-46F2-957B-D5CE5C8A5BEB Q37135110-F354E5D8-5B16-4EE5-A531-966633B988C8 Q37199788-9BD09123-CE9D-473B-9D42-D0A66BEEA8EF Q38842982-560DC2C2-6D5F-4BBD-BD2D-A0095ACA0351 Q42396950-4CF5F584-CF83-4FF9-8E43-1746D576F868 Q46799066-372701EE-63ED-41EE-A233-E11C0B9871CD Q49695446-4799C630-A0BC-4528-9324-A1440347B4C5 Q55035309-C623F5CA-9A27-4862-8291-AFDD14FE3C74

P2860

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis

http://www.wikidata.org/entity/Q35351243

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety and efficacy of nicotin ...... ia in patients on hemodialysis

@ast

Safety and efficacy of nicotin ...... ia in patients on hemodialysis

@en

type

label

Safety and efficacy of nicotin ...... ia in patients on hemodialysis

@ast

Safety and efficacy of nicotin ...... ia in patients on hemodialysis

@en

prefLabel

Safety and efficacy of nicotin ...... ia in patients on hemodialysis

@ast

Safety and efficacy of nicotin ...... ia in patients on hemodialysis

@en

P1433

Q35351243-C548CC2C-FCF4-43BE-BDC3-9C6696CB5093

P1476

Q35351243-BC7AC282-1E13-437B-A9DF-8E064E4A36C7

P2093

Q35351243-32C9B8DA-4231-4C79-BF54-32AB988F95D3

Q35351243-33E8FC3D-7AF4-4BB8-AB56-87EF0E4417D8

Q35351243-42DA4E87-156B-4B15-A7D6-7384777F9425

Q35351243-6A81F2DE-296F-4B0A-B050-4C6BA3B885AE

Q35351243-6E1D1B21-C1EF-4561-8F4E-200D19166985

Q35351243-72C186AC-F11B-4236-A331-469DA4CBEE1B

Q35351243-B3514BD8-C650-4689-B668-A287C9DD523D

P2860

Q35351243-0C536DA1-77CE-49BD-8076-A26ECCE6F999

Q35351243-105C3963-2B8E-458A-BB2D-89F9BCA4F9C2

Q35351243-14BB49EB-596B-4D94-80F6-7846337FC50D

Q35351243-1967A0E8-64EC-44E2-8849-6CF47F670C4A

Q35351243-1AC8A440-99BC-4284-8D15-39CBDC55241D

Q35351243-28C46349-FFD0-4D99-8D19-8D00235832E2

Q35351243-2A85439C-72C8-4235-B31F-C606CF64E9EC

Q35351243-2E4E4069-18DD-4796-AB08-86C6BCAF38C8

Q35351243-33891A8F-4728-45EF-9095-73843E0DAC5D

Q35351243-36C7718D-E22E-4FC2-BE99-32F6406F07DE

P304

Q35351243-63E0CB9F-5E76-474B-A380-5E40E67EB999

P31

Q35351243-360B45FD-B3F0-4F33-807B-5EEF9FE81411

P356

Q35351243-74953B8F-9594-427F-AF2A-5D445469C8CC

P433

Q35351243-BE1AC14E-1E3A-4A39-9012-1C5BD2965B6E

P478

Q35351243-85E2A5D0-3F5D-4EB7-9FD2-7D3C21CE19B3

P577

Q35351243-A67425E5-5E7E-4C75-8AB3-8A68783B5155

P698

Q35351243-64A8CB16-957F-4C93-AC6A-CB30C5C09A2E

P932

Q35351243-1C04696B-5026-4411-B06B-A19D3C0493F3

P356

0971-4065.83735

P1433

Indian Journal of Nephrology

P1476

Safety and efficacy of nicotin ...... ia in patients on hemodialysis

@en

P2093

C Umamaheswara Reddy

http://www.w3.org/2001/XMLSchema#string

G Kannan

http://www.w3.org/2001/XMLSchema#string

G Neenu

http://www.w3.org/2001/XMLSchema#string

J Vasantha

http://www.w3.org/2001/XMLSchema#string

N Vanitharani

http://www.w3.org/2001/XMLSchema#string

P Soundararajan

http://www.w3.org/2001/XMLSchema#string

P Thennarasu

http://www.w3.org/2001/XMLSchema#string

P2860

Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush

Molecular identification of high and low affinity receptors for nicotinic acid

Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid

Characterization of a G protein-coupled receptor for nicotinic acid.

Safety of high-dose nicotinamide: a review.

Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition.

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States.

Central effects of nicotinamide and inosine which are not mediated through benzodiazepine receptors.

P304

245-249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0971-4065.83735

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22022084

http://www.w3.org/2001/XMLSchema#string

P932

3193667

http://www.w3.org/2001/XMLSchema#string